Stock Events

Stock Events

Rallybio 

€14.10
0
-€0.10-0.7% 06:02 Today

Statistics

Day High
14.1
Day Low
14.1
52W High
14.4
52W Low
13.4
Volume
-
Avg. Volume
-
Mkt Cap
74.88M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

5NovExpected
Q1 2026
Q2 2026
Next
-1.24
-1.17
-1.1
-1.02
Expected EPS
-1.238688
Actual EPS
N/A

Financials

-1,113.05%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
745,634.18Revenue
-8.3MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 33M0.F. It's not an investment recommendation.
Microsoft
5
MSFT
Tesla
4
TSLA
Amazon
4
AMZN
NVIDIA
4
NVDA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap137.3B
Vertex Pharmaceuticals is a competitor because it also focuses on developing treatments for rare diseases, similar to Rallybio's focus.
Alnylam Pharmaceuticals
ALNY
Mkt Cap31.73B
Alnylam Pharmaceuticals competes in the rare disease space with its RNAi therapeutics, overlapping with Rallybio's target market.
Biomarin Pharmaceutical
BMRN
Mkt Cap12.52B
BioMarin Pharmaceutical targets rare genetic diseases with its enzyme replacement therapies, competing with Rallybio's approach to rare disorders.
CRISPR Therapeutics
CRSP
Mkt Cap5.58B
CRISPR Therapeutics is involved in gene editing for rare diseases, directly competing with Rallybio's focus on innovative treatments for rare disorders.
Novo Nordisk
NVO
Mkt Cap201.64B
Novo Nordisk, while larger and more diversified, competes with Rallybio in the hemophilia space, a key area of focus for Rallybio.
Sarepta Therapeutics
SRPT
Mkt Cap2.2B
Sarepta Therapeutics' focus on precision genetic medicine, especially for rare diseases like Duchenne muscular dystrophy, places it in competition with Rallybio.
Ultragenyx Pharmaceutical
RARE
Mkt Cap2.52B
Ultragenyx Pharmaceutical targets rare and ultra-rare diseases with its biologic therapies, competing in the same space as Rallybio.
PTC Therapeutics
PTCT
Mkt Cap5.85B
PTC Therapeutics offers treatments for rare disorders, including genetic and neuromuscular diseases, competing with Rallybio's rare disease focus.

About

Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.
Show more...
CEO
Stephen Uden
Employees
7
Country
United States
ISIN
US75120L2097
WKN
000A42087

Listings

F
DE
33M0.F
XNAS
US
RLYB
BOATS
BOATS
RLYB.BOATS

0 Comments

Share your thoughts

FAQ

What is Rallybio stock price today?▼
The current price of 33M0.F is €14.10 EUR — it has decreased by -0.7% in the past 24 hours. Watch Rallybio stock price performance more closely on the chart.
What is Rallybio stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Frankfurt Exchange exchange Rallybio stocks are traded under the ticker 33M0.F.
What is Rallybio market cap?▼
Today Rallybio has the market capitalization of 74.88M
When is the next Rallybio earnings date?▼
Rallybio is going to release the next earnings report on November 05, 2026.
What is Rallybio revenue for the last year?▼
Rallybio revenue for the last year amounts to 745,634.18 EUR.
What is Rallybio net income for the last year?▼
33M0.F net income for the last year is -8.3M EUR.
How many employees does Rallybio have?▼
As of September 04, 2026, the company has 7 employees.
In which sector is Rallybio located?▼
Rallybio operates in the Health & Wellness sector.
When did Rallybio complete a stock split?▼
The last stock split for Rallybio was on February 06, 2026 with a ratio of 1:8.
Where is Rallybio headquartered?▼
Rallybio is headquartered in NEW HAVEN, United States.